There is no clear indication of the need for rituximab after stem cell transplantation, and it is generally necessary to make a comprehensive judgment based on the body’s response after transplantation and the success rate of transplantation.
Rituximab Injection is mainly used for the treatment of relapsed or chemotherapy-resistant inert B-cell non-Hodgkin’s lymphoma. The use of the drug may cause a variety of adverse reactions such as abdominal pain, cardiac arrhythmia, and diarrhea.
Therefore it is contraindicated in people who are allergic to any component of the drug or allergic to mouse proteins. Caution is required in the presence of a large number of malignant cells in the circulation of body fluids or a high tumor load. It should be used with caution in special populations such as children, the elderly or pregnant women.
There is no clear indication for the use of rituximab injection after stem cell transplantation, and the use of rituximab injection should be based on the degree of tumor cell lesions, the extent of the spread of tumor cells in the body, and the effect of stem cell transplantation, and should be treated with caution under the guidance of a doctor.
Stem cell transplant patients should choose the appropriate drugs under the guidance of doctors.